TD completes acquisition of Cowen Inc. Learn more.

Phil Nadeau, Ph.D.

Managing Director, Health Care - Biotechnology

Headshot photo of Phil Nadeau

Philip Nadeau is a managing director and senior research analyst on the biotechnology team at Cowen. He joined Cowen in 2000 and is responsible for covering approximately 25 large-, mid-, and small-cap biotechnology stocks. Cowen’s biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey. Dr. Nadeau has been recognized in The Wall Street Journal’s “Best on the Street” rankings and in the Institutional Investor poll. His views on biotechnology topics are often quoted by national news services such as Reuters, Bloomberg and the Dow Jones newswires. Prior to joining Cowen, he was a research assistant at Children’s Hospital, Boston.

Dr. Nadeau has an SB/MEng in electrical engineering and computer science from MIT and a Ph.D. in Neurobiology from Harvard University. 

Get In Touch

Start a conversation with Phil Nadeau

    Insights

    Explore related thought leadership, reports, coverage and insights for Phil Nadeau.

    Representing research into Obesity drug market is a scale and an exhausted tape measure resting on the scale. Against a white background and the scale is old fashioned.
    Ahead of the Curve®

    Obesity Market Poised to Deliver on Outsized Potential

    Man looking at screen, in the reflection of his eye glasses is info related to BioTech and Health care. Representative of investing in a biotech.
    Ahead of the Curve®

    Generalist’s Guide to Vetting Smid-Cap Biotech: Bear Market Edition

    Petri dish of pills under FDA review. Representative of navigating FDA regulation post Covid.
    Ahead of the Curve®

    Trials & Triumphs of the FDA: What Matters? Where are We?